Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates
| dc.contributor.author | Mulubwa, Mwila | |
| dc.contributor.author | Griesel, Heletje Aletta | |
| dc.contributor.author | Mugabo, Pierre E. | |
| dc.date.accessioned | 2020-12-15T09:08:37Z | |
| dc.date.available | 2020-12-15T09:08:37Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | The pharmacokinetics of vancomycin, a drug used for the treatment of methicillin-resistant Staphylococcus aureus (MRSA), varies between paediatric and adult patients. The objective of this study was to assess the pharmacokinetics of vancomycin in preterm neonates and determine the optimum dose regimen. | en_US |
| dc.identifier.citation | 9. Mulubwa, M. et al (2020). Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates. Drugs in R and D ,20(2), 105-113 | en_US |
| dc.identifier.issn | 1179-6901 | |
| dc.identifier.uri | https://doi.org/10.1007/s40268-020-00302-7 | |
| dc.identifier.uri | http://hdl.handle.net/10566/5516 | |
| dc.language.iso | en | en_US |
| dc.publisher | Springer Nature | en_US |
| dc.subject | Vancomycin pharmacokinetics | en_US |
| dc.subject | Dose regimen | en_US |
| dc.subject | Preterm Neonates | en_US |
| dc.subject | Adult patients | en_US |
| dc.subject | Paediatric | en_US |
| dc.title | Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates | en_US |
| dc.type | Article | en_US |